F
or decades, public health experts and economists have been warning of the enormous human toll and economic losses exerted by tropical diseases, notably malaria, dengue fever, and sleeping sickness. Funding agencies, philanthropies, and pharmaceutical companies have invested millions of dollars and euros into research to find a cure or vaccine. But while these major killers have drawn most of the public, funders' and scientists' attention, it has become clear during the past few years that many other "neglected tropical diseases" (NTDs) also have a considerable impact on the populations and economies of developing countries (Fig 1) .
More recently still, NTDs have become a growing problem for the affluent nations of Europe, North America, South-East Asia, and Australasia where they predominantly affect the poor and disenfranchised. Peter Hortez from the National School of Tropical Medicine at Baylor College of Medicine, Houston, Texas, USA, therefore coined the term "blue marble health"-in reference to an iconic photograph of Earth taken from space-to underline that NTDs occur everywhere on the planet and affect the poor in every country. "I have given this name to differentiate them from old global health paradigms [diseases such as malaria and TB with higher levels of fatality]," said Hortez, who specializes in NTDs in developed countries, especially the USA.
A lthough there are many differences between the NTDs and how they affect their victims, the disease profiles are similar in terms of their adverse impact on child development, pregnancy outcome, and worker productivity [1] . In both developed and developing nations, NTDs tend to have low mortality, measured in years lost, but high morbidity, measured in years lived with some form of disability [2] . This translates into high measures of DALYs (disabilityadjusted life years) lost, which is a common measure of how disease impacts on quality of life and equates to economic productivity.
There are two other important characteristics of NTDs common among many nations. At least in the USA and the developing nations of Latin American and the Caribbean region, these diseases disproportionately affect indigenous and colored people, after taking wealth into account [3] . The situation is similar in parts of Europe where some immigrant groups and Romani people tend to suffer more than others of comparable economic status, according to Hortez. The second common aspect of NTDs is that treatment is relatively inexpensive. Symptoms emerge gradually in the form of skin sores or ulcers weeks or even months after the victim has been bitten. More serious complications can follow a few months to years after infection, including fever, damage to the spleen and liver, and anemia. These are usually associated with a more severe form of the disease called visceral leishmaniasis, which is more likely to afflict vulnerable people with weakened immune systems, notably HIV/AIDS sufferers. "The link with HIV/AIDS was more of an issue during the 1980s and 1990s because when you treat HIV you decrease the risk of co-infection," commented Pécoul. Modern antiretroviral drug treatments for HIV/AIDS, readily available in Europe, alleviate the impact on the immune system and reduce the severity of leishmaniasis in the event of co-infection. There is little transmission of leishmaniasis in the USA, but it has been more of an issue for the country's servicemen stationed abroad. "There has been a lot coming back from Afghanistan or Iraq, places where a lot of transmission occurs," explained Pécoul.
T he USA itself has been more afflicted by Chagas disease, named after the Brazilian physician Carlos Chagas who first described it in 1909. It is caused by the protozoan Trypanosoma cruzi, which is commonly transmitted to humans and other mammals by an insect vector, the bloodsucking "kissing bugs" of the subfamily Triatominae. It can also be transmitted from "By applying published seroprevalence figures to immigrant populations, CDC (Centers for Disease Control and Prevention) estimates that more than 300,000 persons with Trypanosoma cruzi infection live in the United States," said Monica Parise, the CDC's head of parasitic infections. Indeed, the incidence of Chagas is now increasing across both the USA and Europe, according to Pécoul. Again, Spain seems to be affected worst, with around 70,000 people infected [4] .
The pathology of Chagas has an early acute phase, followed by a chronic condition that is potentially more serious. Symptoms in the acute phase involve local swelling around the site of the bite and antiparasitic drug treatment yields a complete cure in about 60-85% of adults and more than 90% of infants treated in the first year of acute phase. However, the success of drug treatments in clearing the pathogen diminishes significantly after even four to eight weeks by which time the infection enters a chronic phase in 20-40% of Chagas sufferers who often develop life-threatening cardiac or digestive disorders.
In the case of leishmaniasis, a number of drugs have been tried with varying degrees of success. The most promising candidate is miltefosine, which was initially developed in the late 1980s as an anticancer agent by German scientists Hansjörg Eibl and Clemens Unger. The drug is also effective against the Leishmania protozoa and is now being used as a broad-spectrum antimicrobial drug against pathogenic bacteria and fungi: it targets the phospholipids that are major components of the parasites' cell membranes. Yet, even if drugs are important, it requires sound public health policies in addition to therapeutic measures, according to Parise. She singled out Chagas in particular given that two available drugs, nifurtimox and benznidazole, have serious side effects. The CDC's efforts to deal with the disease include education of health professionals, supporting physicians and patients with diagnostic testing, developing improved diagnostic tests for Chagas disease and ways to determine whether treatment has been successful, and collaborating with investigators to determine the congenital risk of Chagas disease among at-risk mothers, Parise commented.
W
hile Chagas and leishmaniasis are the leading NTDs in North America and Europe, the situation is different in other developed nations where Buruli ulcer can be an equally significant disease: in 2013, 105 cases were reported in Australia (http://apps.who. int/neglected_diseases/ntddata/buruli/buruli. html). This disease is caused by Mycobacterium ulcerans, which is related to Mycobacterium leprae, the cause of leprosy and the Mycobacteria that cause tuberculosis. As the name indicates, Buruli ulcer is a chronic, debilitating infection characterized by skin ulcerations that expand into necrotizing lesions of dead skin and occasionally surrounding bone, which, if untreated, leads to permanent scarring and in some causes requiring amputation. It is largely confined to tropical and subtropical areas but it also afflicts parts of Australia and other countries including Japan.
Alongside treatment, research has focused particularly on the transmission mechanism, which remains largely unknown; it has gained Buruli ulcer the term "the mysterious disease". It is associated with tropical and subtropical aquatic environments, and M. ulcerans has been detected as biofilms on surfaces, including adult mosquitoes [5] . But it has yet to be established beyond doubt whether it spreads to humans via mosquito bites, or some form of contamination from the environment. Direct human-to-human transmission has not been observed except in one case, but there is evidence that it occurs as a zoonosis, according to John Wallace, a medical entomologist specializing in Buruli ulcer at Millersville University in Pennsylvania, USA. "BU cases have been confirmed in multiple mammalian species, such as Koala, Potoroo, Possums, horses, and dogs and there may be a few others such as roos and maybe a snake too," he said. But even the latest research does not finally resolve the mystery, since it seems to suggest that the bacterium does not cause infection via open wounds. "We have a paper under review based on laboratory work showing that we are unable to get infection in a guinea pig model of infection simply by dropping bacteria on an open wound," Wallace explained. "The results were totally unexpected in that the bacteria must be injected into the skin to establish infection. This was quite surprising because if you drop Staph or other infectious skin pathogens on an open wound, they do replicate and cause disease. Although it was a lab study, we think it provides fairly good evidence that the bacteria are not likely to establish infection passively through an open wound." One reason it has proved difficult to establish the transmission mechanism for M. ulcerans is the long incubation period, which makes it hard to associate infection with a particular incident such as an insect bite or skin abrasion, according to Wallace. 
